Summaries for patients. HIV lipodystrophy: rosiglitazone or metformin?  [electronic resource] 

 -  Annals of internal medicine  Sep 2005 
 - I38 p.  digital 
<br/><br/> Publication Type: Comparative Study; Patient Education Handout; Research Support, Non-U.S. Gov't; Journal Article 
<br/><br/><label>ISSN: </label>1539-3704 
<br/><br/><label>Standard No.: </label>10.7326/0003-4819-143-5-200509060-00004  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adipose Tissue--metabolism<br/>Adolescent<br/>Adult<br/>Aged<br/>Blood Glucose--metabolism<br/>Brachial Artery--physiology<br/>Endothelium, Vascular--metabolism<br/>Fatty Acids, Nonesterified--blood<br/>Glucose Tolerance Test<br/>HIV Infections--complications<br/>Humans<br/>Hypoglycemic Agents--adverse effects<br/>Insulin--blood<br/>Lipodystrophy--drug therapy<br/>Male<br/>Metformin--adverse effects<br/>Middle Aged<br/>PPAR gamma--agonists<br/>Rosiglitazone<br/>Thiazolidinediones--adverse effects<br/>Vasodilation--drug effects